OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1588-1597
Open Access | Times Cited: 14
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1588-1597
Open Access | Times Cited: 14
Showing 14 citing articles:
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021
Xinyue Gou, Zhuo Chen, Y. Shangguan
Frontiers in Oncology (2025) Vol. 15
Open Access
Xinyue Gou, Zhuo Chen, Y. Shangguan
Frontiers in Oncology (2025) Vol. 15
Open Access
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002 : A phase 2 study comparing jaktinib at 100 mg twice daily (BID ) and 200 mg once daily (QD ) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
Momelotinib in myelofibrosis
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 521-528
Closed Access | Times Cited: 2
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 521-528
Closed Access | Times Cited: 2
Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors
Nazanin Aghel, Rocío Consuelo Baro Vila, Michelle Lui, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 9, pp. 941-958
Closed Access | Times Cited: 3
Nazanin Aghel, Rocío Consuelo Baro Vila, Michelle Lui, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 9, pp. 941-958
Closed Access | Times Cited: 3
Jaktinib and momelotinib for the treatment of myelofibrosis—Birds of a feather?
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1517-1519
Closed Access | Times Cited: 2
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1517-1519
Closed Access | Times Cited: 2
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
Yıldız İpek, Berkay Kılıç, Ü. Günay, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 10, pp. 931-940
Closed Access | Times Cited: 2
Yıldız İpek, Berkay Kılıç, Ü. Günay, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 10, pp. 931-940
Closed Access | Times Cited: 2
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients
Meiling Tang, Ying Chen, Yanying Zhou, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
Meiling Tang, Ying Chen, Yanying Zhou, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Yi Zhang, Hu Zhou, Shanshan Suo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
Yi Zhang, Hu Zhou, Shanshan Suo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
Zerong Wang, Xuelian Jin, Jiajia Zeng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3293-3301
Open Access
Zerong Wang, Xuelian Jin, Jiajia Zeng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3293-3301
Open Access
Recent advances in JAK2 inhibition for the treatment of myelofibrosis
Noa Rippel, Marina Kremyanskaya
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1175-1186
Closed Access
Noa Rippel, Marina Kremyanskaya
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1175-1186
Closed Access
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Xingpeng Di, Ya Li, Jingwen Wei, et al.
Advanced Science (2024)
Open Access
Xingpeng Di, Ya Li, Jingwen Wei, et al.
Advanced Science (2024)
Open Access
